Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis

Magen et al. discovered new miRNA-based biomarkers in the blood of patients with ALS. miR-181 levels alone or in combination with an established protein biomarker predict ALS severity and prognosis and might enhance the power of clinical trials. Amyotrophic lateral sclerosis (ALS) is a relentless neurodegenerative disease of the human motor neuron system, where variability in progression rate limits clinical trial efficacy. Therefore, better prognostication will facilitate therapeutic progress. In this study, we investigated the potential of plasma cell-free microRNAs (miRNAs) as ALS prognostication biomarkers in 252 patients with detailed clinical phenotyping. First, we identified, in a longitudinal cohort, miRNAs whose plasma levels remain stable over the course of disease. Next, we showed that high levels of miR-181, a miRNA enriched in neurons, predicts a greater than two-fold risk of death in independent discovery and replication cohorts (126 and 122 patients, respectively). miR-181 performance is similar to neurofilament light chain (NfL), and when combined together, miR-181 + NfL establish a novel RNA-protein biomarker pair with superior prognostication capacity. Therefore, plasma miR-181 alone and a novel miRNA-protein biomarker approach, based on miR-181 + NfL, boost precision of patient stratification. miR-181-based ALS biomarkers encourage additional validation and might enhance the power of clinical trials.

Automated summary

The study identified miRNA-based biomarkers in the blood of ALS patients, with miR-181 levels alone or in combination with established protein biomarkers predicting disease severity and prognosis. This approach may enhance the power of clinical trials for ALS and improve patient stratification accuracy.